How combining an evolutionary perspective with genomic methods can advance CLL treatment

How combining an evolutionary perspective with genomic methods can advance CLL treatment

VJHemOnc

3 years
1,309 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dan Landau, MD, PhD of Weill Cornell Medical College and the NYGC, New York, NY gives an overview of his talk on clonal evolution in chronic lymphocytic leukemia (CLL) held at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Dr Landau explains that we understand that a malignant population such as a population of CLL cells in any patient, is actually not uniform but composed of multiple subpopulations, which continuously compete, evolve and create diversity. The therapeutic challenge is that in each patient, we are not dealing with one disease but with a collection of many diseases. Therefore, it is not surprising that therapies can fail. With new genomic technologies, it is now possible to survey this genetic complexity for large cohorts of patients in order to understand the processes underlying the complexity. By taking an evolutionary perspective and combining it with genomic methods, we can infer the past history of disease and use this information to predict its future. Dr Landau points out how today data science approaches are already being used to predict real world outcomes in advertising or on the stock market for example. However, data science approaches are not really being applied in cancer research. Further, he discusses non-genetic sources of diversity, such as epigenetics and spatial location. All of these layers of information need to be considered in order to understand the evolutionary process. Finally, he discusses the idea of measuring clonal kinetics directly in patients, i.e. measuring the rate of growth of each clone with each therapy and come up with an optimized therapeutic approach through the use of algorithms; he considers this approach to be a radical extension of the precision medicine paradigm.
Up Next Autoplay
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
5 Views
Cancer-News 14 hours
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 16 hours
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
7 Views
kidneycancer 17 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 18 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
7 Views
kidneycancer 2 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 2 days
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
7 Views
kidneycancer 3 days